Iclusig for CML/ALL

Iclusig (ponatinib) has now been FDA approved for the treatment of CML and certain types of ALL.

Cometriq for Medullary Thyroid Cancer

Cometriq (cabozantinib) is now FDA approved for the treatment of progressive metastatic medullary thyroid cancer. It is an oral chemotherapy involved in inhibiting multiple tyrosine kinases which are involved with cancer growth and spread. 

Abraxane added to Gemzar helps in metastatic pancreatic cancer

Preliminary results of a recent clinical trial shows a survival benefit when Abraxane (modified Taxol) is added to Gemzar for treatment of metastatic pancreatic cancer.  Full results of the study to be announced in January 2014.

Synribo for CML

Synribo (injectable) now approved for CML patients with resistance or intolerance to 2 or more TKIs.

Liquid tamoxifen now available

A liquid form of tamoxifen is now available for breast cancer patients who have trouble swallowing tablets. It's called Soltamox Oral Solution, marketed by DARA BioSiences. 

Bosulif now approved in CML

Bosulif (bosutinib) has been recently approved as a new treatment in CML. It is used as second-line therapy in the case of disease progression or intolerance to first-line treatment. Efficacy is comparable to currently available second-line treatments. 

Alimta maintenance for NSCLC

Alimta now approved as maintenance therapy every 3 weeks after completion of combination therapy with cisplatin for locally advanced or metastatic non-squamous non-small cell lung cancer.